Frontiers in pharmacology · 2026
Review Areca Thirteen Pill (GY-13) for depression: a ConPhyMP-Informed critical review of material definition, pharmacological evidence, and translational Heyi-neuroplasticity-stress hypotheses.
СтатьяОбзорНазвание и аннотация: Перевод пока не подготовлен
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Dai Narisu, Bao Zhiying, Chen Xiaomin
Аннотация
UNLABELLED: Previous summaries of GY-13 have lacked transparent literature-search methods, reproducible material definitions, chemical-characterization status, or critical evidence grading, limiting their scientific utility.
OBJECTIVE: This review critically evaluates what the published GY-13 literature shows and does not show regarding antidepressant pharmacology, material reproducibility, clinical evidence, and safety. It also reformulates the Heyi-Neuroplasticity-Stress (HNS) framework as a testable translational hypothesis rather than as a confirmed mechanism.
METHODS: This critical scoping review was reported using a PRISMA-informed approach, with PRISMA-ScR, the Four Pillars of Best Practice in Ethnopharmacology, and ConPhyMP used as reporting and interpretive frameworks. Searches were rerun on 3 June 2026 in PubMed/MEDLINE and CNKI, supplemented by public bibliographic records and citation checking. Thirty records were identified; after deduplication and screening, 12 studies or contextual records were retained. The review was not prospectively registered, screening and extraction were not performed by two independent reviewers, and no validated design-specific risk-of-bias tool was applied. These limitations preclude designation as a fully systematic review.
RESULTS: The available evidence supports the possibility that GY-13 affects depression-related behavioral and molecular endpoints in stress-based animal models, including cAMP/PKA/CREB/BDNF signaling, HPA-axis feedback, monoamine signaling, inflammatory-oxidative pathways, and chemokine-axis findings. However, the reproducibility of these findings is limited by incomplete reporting of batch identity, voucher/authentication data, manufacturing details, HPLC/UPLC or LC-MS fingerprints, marker-metabolite quantification, dose-response structure, and randomization/blinding. Human evidence remains preliminary and insufficient for definitive clinical-efficacy claims.
CONCLUSION: GY-13 is best treated as a hypothesis-generating multi-component intervention requiring chemically defined batches, strict ConPhyMP documentation, independent preclinical replication, and well-powered clinical trials with standardized safety monitoring. The HNS framework may guide future biomarker-enriched research only if tested prospectively with transparent materials and methods.
OBJECTIVE: This review critically evaluates what the published GY-13 literature shows and does not show regarding antidepressant pharmacology, material reproducibility, clinical evidence, and safety. It also reformulates the Heyi-Neuroplasticity-Stress (HNS) framework as a testable translational hypothesis rather than as a confirmed mechanism.
METHODS: This critical scoping review was reported using a PRISMA-informed approach, with PRISMA-ScR, the Four Pillars of Best Practice in Ethnopharmacology, and ConPhyMP used as reporting and interpretive frameworks. Searches were rerun on 3 June 2026 in PubMed/MEDLINE and CNKI, supplemented by public bibliographic records and citation checking. Thirty records were identified; after deduplication and screening, 12 studies or contextual records were retained. The review was not prospectively registered, screening and extraction were not performed by two independent reviewers, and no validated design-specific risk-of-bias tool was applied. These limitations preclude designation as a fully systematic review.
RESULTS: The available evidence supports the possibility that GY-13 affects depression-related behavioral and molecular endpoints in stress-based animal models, including cAMP/PKA/CREB/BDNF signaling, HPA-axis feedback, monoamine signaling, inflammatory-oxidative pathways, and chemokine-axis findings. However, the reproducibility of these findings is limited by incomplete reporting of batch identity, voucher/authentication data, manufacturing details, HPLC/UPLC or LC-MS fingerprints, marker-metabolite quantification, dose-response structure, and randomization/blinding. Human evidence remains preliminary and insufficient for definitive clinical-efficacy claims.
CONCLUSION: GY-13 is best treated as a hypothesis-generating multi-component intervention requiring chemically defined batches, strict ConPhyMP documentation, independent preclinical replication, and well-powered clinical trials with standardized safety monitoring. The HNS framework may guide future biomarker-enriched research only if tested prospectively with transparent materials and methods.